AU2011309762B2 - Pharmaceutical composition - Google Patents

Pharmaceutical composition Download PDF

Info

Publication number
AU2011309762B2
AU2011309762B2 AU2011309762A AU2011309762A AU2011309762B2 AU 2011309762 B2 AU2011309762 B2 AU 2011309762B2 AU 2011309762 A AU2011309762 A AU 2011309762A AU 2011309762 A AU2011309762 A AU 2011309762A AU 2011309762 B2 AU2011309762 B2 AU 2011309762B2
Authority
AU
Australia
Prior art keywords
composition
carbetocin
composition according
methionine
buffer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2011309762A
Other languages
English (en)
Other versions
AU2011309762A1 (en
Inventor
Mattias Malm
Anders Nilsson
Britta Siekmann
Kazimierz Wisniewski
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ferring BV
Original Assignee
Ferring BV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43478408&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AU2011309762(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Ferring BV filed Critical Ferring BV
Publication of AU2011309762A1 publication Critical patent/AU2011309762A1/en
Priority to AU2013204097A priority Critical patent/AU2013204097B2/en
Priority to AU2013204095A priority patent/AU2013204095B2/en
Application granted granted Critical
Publication of AU2011309762B2 publication Critical patent/AU2011309762B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A61K38/095—Oxytocins; Vasopressins; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10—Laxatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/04—Drugs for genital or sexual disorders; Contraceptives for inducing labour or abortion; Uterotonics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/06—Antiabortive agents; Labour repressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/14—Drugs for genital or sexual disorders; Contraceptives for lactation disorders, e.g. galactorrhoea
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/10—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Dermatology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Otolaryngology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Pain & Pain Management (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Inorganic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Psychiatry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Communicable Diseases (AREA)
AU2011309762A 2010-09-30 2011-09-29 Pharmaceutical composition Active AU2011309762B2 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
AU2013204097A AU2013204097B2 (en) 2010-09-30 2013-04-11 Pharmaceutical composition
AU2013204095A AU2013204095B2 (en) 2010-09-30 2013-04-11 Pharmaceutical composition

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP10251690.3 2010-09-30
EP10251690 2010-09-30
PCT/IB2011/002394 WO2012042371A2 (en) 2010-09-30 2011-09-29 Pharmaceutical composition

Related Child Applications (2)

Application Number Title Priority Date Filing Date
AU2013204097A Division AU2013204097B2 (en) 2010-09-30 2013-04-11 Pharmaceutical composition
AU2013204095A Division AU2013204095B2 (en) 2010-09-30 2013-04-11 Pharmaceutical composition

Publications (2)

Publication Number Publication Date
AU2011309762A1 AU2011309762A1 (en) 2013-04-04
AU2011309762B2 true AU2011309762B2 (en) 2014-07-17

Family

ID=43478408

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2011309762A Active AU2011309762B2 (en) 2010-09-30 2011-09-29 Pharmaceutical composition

Country Status (27)

Country Link
US (4) US9566311B2 (enExample)
EP (5) EP3222272B1 (enExample)
JP (2) JP6038797B2 (enExample)
KR (2) KR101919119B1 (enExample)
CN (4) CN104906032A (enExample)
AU (1) AU2011309762B2 (enExample)
BR (2) BR122021001123B1 (enExample)
CA (1) CA2812510A1 (enExample)
CY (2) CY1119245T1 (enExample)
DK (4) DK4374878T3 (enExample)
ES (4) ES2637988T3 (enExample)
FI (1) FI4374878T3 (enExample)
HR (3) HRP20171256T1 (enExample)
HU (4) HUE034367T2 (enExample)
IL (3) IL225238B (enExample)
JO (3) JO3400B1 (enExample)
LT (3) LT4374878T (enExample)
MX (3) MX395271B (enExample)
NZ (1) NZ609719A (enExample)
PL (4) PL4374878T3 (enExample)
PT (4) PT3222272T (enExample)
RS (3) RS62873B1 (enExample)
RU (2) RU2737264C2 (enExample)
SI (4) SI4374878T1 (enExample)
SM (3) SMT202500165T1 (enExample)
TW (6) TWI750934B (enExample)
WO (1) WO2012042371A2 (enExample)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070224184A1 (en) * 2006-02-22 2007-09-27 The Research Foundation Of The State University Of New York Method for treating cellulite
US20150099703A1 (en) * 2012-05-08 2015-04-09 Dilafor Ab Treatment of postpartum haemorrhage with chemically modified heparin or heparan sulphate and a uterotonic agent
RS65144B1 (sr) * 2014-09-19 2024-02-29 Ferring Bv Postupak za lečenje prader-vilijevog sindroma
RU2719416C2 (ru) 2014-10-01 2020-04-17 Окситон Байосайенс Б.В. Перорально распадающаяся твердая фармацевтическая единица дозирования, содержащая контролирующее родовую деятельность вещество
CN106999436B (zh) 2014-10-01 2021-07-02 奥克希托恩生物科学公司 含有分娩控制物质的口服崩解固体药物剂量单元
PL3242676T3 (pl) 2015-01-07 2024-07-15 Tonix Pharma Limited Preparaty oksytocyny zawierające magnez i sposoby ich stosowania
WO2016162819A1 (en) * 2015-04-07 2016-10-13 Lupin Limited Stable aqueous pharmaceutical composition of anti-tnf alpha antibody
HRP20250215T1 (hr) 2016-04-12 2025-06-20 Tonix Pharma Limited Formulacije oksitocina koje sadrže magnezij i postupci upotrebe
CN107773531B (zh) * 2016-08-31 2021-05-04 成都倍特药业股份有限公司 一种马来酸麦角新碱注射液
CN108236601B (zh) * 2016-12-23 2020-04-17 深圳翰宇药业股份有限公司 一种稳定的含卡贝缩宫素的阴道给药的药用组合物及其制备方法
AU2018312956B2 (en) * 2017-08-11 2022-03-10 Ferring B.V. Method of manufacturing a pharmaceutical composition
GB201721846D0 (en) * 2017-12-22 2018-02-07 Arecor Ltd Novel composition
EP3759121A1 (en) 2018-03-01 2021-01-06 Trigemina, Inc. Labeled oxytocin and method of manufacture and use
CN108721598B (zh) * 2018-07-03 2020-06-05 北京市新里程医药科技有限公司 一种缩宫素原料的制备方法及其药物组合物和制剂
US20200093884A1 (en) * 2018-09-20 2020-03-26 Mark C. Manning Stable intranasal formulations of carbetocin
EP3852724A4 (en) 2018-09-20 2022-07-06 Levo Therapeutics, Inc. CARBETOCIN DRUG PRODUCT AND PROCESS FOR ITS MANUFACTURE
CN109745544B (zh) * 2018-11-23 2024-11-08 南京新百药业有限公司 稳定的缩宫素药物组合物及其制备方法
EP3897571A1 (en) * 2018-12-21 2021-10-27 Arecor Limited Novel composition
WO2020137880A1 (ja) * 2018-12-27 2020-07-02 国立大学法人北海道大学 オキシトシン誘導体及びその使用
KR20220011697A (ko) 2019-05-22 2022-01-28 바이오비에 아이앤씨. 테를리프레신 제형
CN110308222A (zh) * 2019-07-17 2019-10-08 武汉赛沃医药科技有限公司 一种卡贝缩宫素原料药有关物质检测方法
CN110403904A (zh) * 2019-07-26 2019-11-05 翔宇药业股份有限公司 卡贝缩宫素注射液及其应用
CN110237230A (zh) * 2019-07-31 2019-09-17 南京康舟医药科技有限公司 一种卡贝缩宫素药物组合物及其制备方法
WO2021089554A1 (en) 2019-11-04 2021-05-14 Ferring B.V. Intranasal administration of merotocin for improving lactation
CN111012739A (zh) * 2019-12-04 2020-04-17 长春圣金诺生物制药有限公司 一种可以常温储存的含卡贝缩宫素及稳定剂的注射液
WO2022200568A1 (en) 2021-03-26 2022-09-29 Ot4B Treatment of dysphagia
CN114191388B (zh) * 2021-12-27 2023-06-09 苏州天马医药集团天吉生物制药有限公司 一种卡贝缩宫素制剂的制备方法
CN114712483B (zh) * 2022-05-12 2023-09-29 成都倍特药业股份有限公司 一种麦角新碱缩宫素复方注射液及其制备方法和用途
US12214010B2 (en) 2023-04-04 2025-02-04 Tulex Pharmaceuticals Inc. Desmopressin oral compositions

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995001185A1 (en) * 1993-06-29 1995-01-12 Ferring B.V. Stabilized pharmaceutical peptide compositions
US20010027177A1 (en) * 2000-02-04 2001-10-04 Wayne Woodrow Pharmaceutical composition containing a small or medium size peptide
US20030119728A1 (en) * 2000-02-16 2003-06-26 Helmut Scheidl Stable, nasally, orally or sublingually applicable pharmaceutical preparation
WO2008042452A1 (en) * 2006-09-29 2008-04-10 Nastech Pharmaceutical Company Inc. Pharmaceutical compositions comprising oxytocin or an analog for the treatment of autism
WO2008150305A1 (en) * 2007-06-07 2008-12-11 Nastech Pharmaceutical Company Inc. Intranasal carbetocin formulations and methods for the treatment of autism
WO2009122285A1 (en) * 2008-03-31 2009-10-08 Ferring B.V. Oxitocin analogues
EP2174652A2 (en) * 2007-08-06 2010-04-14 GP Pharm S.A. Oral pharmaceutical desmopressin composition

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1109558A (zh) * 1994-11-07 1995-10-04 马文亮 装有压力表的双管气筒
SE9604341D0 (sv) * 1996-11-26 1996-11-26 Ferring Bv Hepta-peptide oxytocin analogue
DE69736140T2 (de) 1997-11-18 2007-04-19 Uni-Pharma Kleon Tsetis Pharmaceutical Laboratories S.A. Pharmazeutische injizierbare Lösungen, die Paracetamol und Kombinationen aus Paracetamol mit anderen Aktivsubstanzen enthalten
US6333313B1 (en) 1998-10-29 2001-12-25 Board Of Regents, The University Of Texas System Clinical use of oxytocin alone or in combination to treat bone disorders
US6894026B1 (en) * 2000-01-11 2005-05-17 Atossa Healthcare, Inc. Long-acting oxytocin analogues for the treatment and prevention of breast cancer and psychiatric disorders
US20030138417A1 (en) 2001-11-08 2003-07-24 Kaisheva Elizabet A. Stable liquid pharmaceutical formulation of IgG antibodies
ATE477811T1 (de) 2002-10-03 2010-09-15 Neuropharmacology Services Llc Oxytocin zur behandlung von autismus und asperger-syndrom
ES2321297T3 (es) 2003-01-08 2009-06-04 Novartis Vaccines And Diagnostics, Inc. Composiciones acuosas estabilizadas que comprenden inhibidor de la via del factor tisular (ivft) o variante del inhibidor de la via del factor tisular.
WO2004078147A2 (en) 2003-03-05 2004-09-16 Pr Pharmaceuticals Oxytocin controlled release formulations and methods of using same
GT200600031A (es) * 2005-01-28 2006-08-29 Formulacion anticuerpo anti a beta
SI2162011T1 (sl) 2007-07-02 2011-05-31 Sime Darby Malaysia Berhad Mešanica rastlinskih maščob in jedilni proizvodi, ki vsebujejo takšno mešanico maščob
CN104013569A (zh) * 2008-10-15 2014-09-03 精达制药公司 高浓缩药物颗粒、制剂、混悬剂及其应用

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995001185A1 (en) * 1993-06-29 1995-01-12 Ferring B.V. Stabilized pharmaceutical peptide compositions
US20010027177A1 (en) * 2000-02-04 2001-10-04 Wayne Woodrow Pharmaceutical composition containing a small or medium size peptide
US20030119728A1 (en) * 2000-02-16 2003-06-26 Helmut Scheidl Stable, nasally, orally or sublingually applicable pharmaceutical preparation
WO2008042452A1 (en) * 2006-09-29 2008-04-10 Nastech Pharmaceutical Company Inc. Pharmaceutical compositions comprising oxytocin or an analog for the treatment of autism
WO2008150305A1 (en) * 2007-06-07 2008-12-11 Nastech Pharmaceutical Company Inc. Intranasal carbetocin formulations and methods for the treatment of autism
EP2174652A2 (en) * 2007-08-06 2010-04-14 GP Pharm S.A. Oral pharmaceutical desmopressin composition
WO2009122285A1 (en) * 2008-03-31 2009-10-08 Ferring B.V. Oxitocin analogues

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
RATH W., "Prevention of postpartum haemorrhage with the oxytocin analogue carbetocin", EUROPEAN JOURNAL OF OBSTETRICS & GYNECOLOGY AND REPRODUCTIVE BIOLOGY, 2009, vol. 147, no. 1, pages 15-20 *

Also Published As

Publication number Publication date
SI3222272T1 (sl) 2022-01-31
JOP20180102B1 (ar) 2022-03-15
TWI750934B (zh) 2021-12-21
PT2621468T (pt) 2017-09-08
PL3246018T3 (pl) 2022-05-02
PT4374878T (pt) 2025-05-02
DK4374878T3 (da) 2025-05-05
SI3246018T1 (sl) 2022-02-28
IL245326B (en) 2021-04-29
US20170106044A1 (en) 2017-04-20
US20170106043A1 (en) 2017-04-20
TWI680773B (zh) 2020-01-01
IL245326A0 (en) 2016-06-30
MX352949B (es) 2017-12-15
EP3246018B1 (en) 2021-11-03
TW201729797A (zh) 2017-09-01
SI2621468T1 (sl) 2017-10-30
SMT201700420T1 (it) 2017-11-15
CY1119245T1 (el) 2018-02-14
EP4374878A2 (en) 2024-05-29
HUE034367T2 (en) 2018-02-28
RS66759B1 (sr) 2025-05-30
US20230124105A1 (en) 2023-04-20
RU2604690C2 (ru) 2016-12-10
HUE070972T2 (hu) 2025-07-28
CN107412728A (zh) 2017-12-01
TWI650134B (zh) 2019-02-11
DK3246018T3 (da) 2022-01-17
ES2905561T3 (es) 2022-04-11
IL225238B (en) 2018-07-31
HRP20171256T1 (hr) 2017-10-20
US20130210746A1 (en) 2013-08-15
SMT202500165T1 (it) 2025-05-12
BR122021001123B1 (pt) 2021-05-18
RS62873B1 (sr) 2022-02-28
LT2621468T (lt) 2017-11-27
HUE056835T2 (hu) 2022-03-28
MX390779B (es) 2025-03-21
JP6250770B2 (ja) 2017-12-20
HRP20211969T1 (hr) 2022-03-18
EP2621468B1 (en) 2017-06-14
EP2621468A2 (en) 2013-08-07
LT4374878T (lt) 2025-04-25
TW201940188A (zh) 2019-10-16
IL225238A0 (en) 2013-06-27
KR20180123599A (ko) 2018-11-16
RU2737264C2 (ru) 2020-11-26
HRP20250382T1 (hr) 2025-05-23
MX395271B (es) 2025-03-21
PL4374878T3 (pl) 2025-06-09
SI4374878T1 (sl) 2025-06-30
TW201605466A (zh) 2016-02-16
JOP20180103B1 (ar) 2022-03-15
SMT202200034T1 (it) 2022-03-21
HK1246170A1 (en) 2018-09-07
RS56220B1 (sr) 2017-11-30
RU2013112666A (ru) 2014-11-10
CY1124924T1 (el) 2023-01-05
FI4374878T3 (fi) 2025-05-16
RU2016143751A3 (enExample) 2020-01-16
PT3222272T (pt) 2022-01-27
TW201219051A (en) 2012-05-16
EP3246018A1 (en) 2017-11-22
PT3246018T (pt) 2022-01-13
PL3222272T3 (pl) 2022-03-07
BR112013007362A2 (pt) 2016-07-12
TW201605465A (zh) 2016-02-16
JP2013543492A (ja) 2013-12-05
RU2016143751A (ru) 2018-12-18
TWI661834B (zh) 2019-06-11
KR20130136467A (ko) 2013-12-12
TW202112389A (zh) 2021-04-01
EP3222272A1 (en) 2017-09-27
IL245328A0 (en) 2016-06-30
WO2012042371A3 (en) 2013-04-04
ES3027637T3 (en) 2025-06-16
IL245328B (en) 2022-04-01
MX2013003365A (es) 2013-07-29
TWI532507B (zh) 2016-05-11
HUE057187T2 (hu) 2022-04-28
LT3222272T (lt) 2021-12-27
EP3222272B1 (en) 2021-11-03
JO3400B1 (ar) 2019-10-20
CA2812510A1 (en) 2012-04-05
WO2012042371A2 (en) 2012-04-05
ES2902418T3 (es) 2022-03-28
CN107080832A (zh) 2017-08-22
AU2011309762A1 (en) 2013-04-04
TWI746951B (zh) 2021-11-21
JP2017048226A (ja) 2017-03-09
DK3222272T3 (da) 2022-01-24
KR102102664B1 (ko) 2020-04-22
CN103124554A (zh) 2013-05-29
DK2621468T3 (en) 2017-09-11
BR112013007362B1 (pt) 2021-05-25
CN107080832B (zh) 2021-05-07
NZ609719A (en) 2014-07-25
KR101919119B1 (ko) 2018-11-15
JOP20180102A1 (ar) 2019-01-30
CN104906032A (zh) 2015-09-16
US9566311B2 (en) 2017-02-14
JP6038797B2 (ja) 2016-12-07
EP4374878B1 (en) 2025-02-12
JOP20180103A1 (ar) 2019-01-30
PL2621468T3 (pl) 2017-11-30
EP3936117A1 (en) 2022-01-12
EP4374878A3 (en) 2024-07-24
ES2637988T3 (es) 2017-10-18

Similar Documents

Publication Publication Date Title
US20230124105A1 (en) Pharmaceutical composition
HK40064553A (en) Pharmaceutical composition
HK40110268B (en) Pharmaceutical composition comprising carbetocin
HK40110268A (en) Pharmaceutical composition comprising carbetocin
HK1244442A1 (en) Pharmaceutical composition
AU2013204097A1 (en) Pharmaceutical composition
HK1244442B (en) Pharmaceutical composition of carbetocin
HK1246170B (en) Pharmaceutical composition
HK1181686A (en) Pharmaceutical composition

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)